These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24513278)

  • 1. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and the rational selection of dosage regimes for the prudent use of antimicrobial drugs.
    Papich MG
    Vet Microbiol; 2014 Jul; 171(3-4):480-6. PubMed ID: 24513278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis.
    Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH
    Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
    Frei CR; Wiederhold NP; Burgess DS
    J Antimicrob Chemother; 2008 Mar; 61(3):621-8. PubMed ID: 18252694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetic/pharmacodynamic paradigm for antimicrobial drugs in veterinary medicine: Recent advances and critical appraisal.
    Toutain PL; Pelligand L; Lees P; Bousquet-Mélou A; Ferran AA; Turnidge JD
    J Vet Pharmacol Ther; 2021 Mar; 44(2):172-200. PubMed ID: 33089523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacokinetic and pharmacodynamic aspects of interpretive reading of the antibiogram].
    Soriano-García F
    Enferm Infecc Microbiol Clin; 2010; 28(7):461-6. PubMed ID: 20381925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated
    Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Andes D; Arendrup MC; Mouton JW; Meletiadis J
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
    Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
    Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro Dynamic Pharmacokinetic/Pharmacodynamic (PK/PD) study and COPD of Marbofloxacin against Haemophilus parasuis.
    Sun J; Xiao X; Huang RJ; Yang T; Chen Y; Fang X; Huang T; Zhou YF; Liu YH
    BMC Vet Res; 2015 Dec; 11():293. PubMed ID: 26626889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.
    Maglio D; Nicolau DP
    Methods Find Exp Clin Pharmacol; 2004 Dec; 26(10):781-8. PubMed ID: 15672121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.
    Bulik CC; Bader JC; Zhang L; Van Wart SA; Rubino CM; Bhavnani SM; Sweeney KL; Ambrose PG
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):161-177. PubMed ID: 28353185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.
    Booker BM; Smith PF; Forrest A; Bullock J; Kelchlin P; Bhavnani SM; Jones RN; Ambrose PG
    Antimicrob Agents Chemother; 2005 May; 49(5):1775-81. PubMed ID: 15855495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampin breakpoint for Acinetobacter baumannii based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
    Lepe JA; García-Cabrera E; Gil-Navarro MV; Aznar J
    Rev Esp Quimioter; 2012 Jun; 25(2):134-8. PubMed ID: 22707102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.
    Dudley MN; Ambrose PG
    Curr Opin Microbiol; 2000 Oct; 3(5):515-21. PubMed ID: 11050452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.